SKGEL® Implant Versus T-Flux® Implant in the Contralateral Eye in Deep Sclerectomy with Phacoemulsification: Long-Term Follow-Up
Frank Schreyger, Gabor Scharioth, Holger Baatz*
Identifiers and Pagination:Year: 2008
First Page: 57
Last Page: 61
Publisher Id: TOOPHTJ-2-57
Article History:Received Date: 8/1/2008
Revision Received Date: 5/3/2008
Acceptance Date: 9/3/2008
Electronic publication date: 28/3/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/) which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
To intraindividually compare the efficacy and safety of the SKGEL® implant versus the T-Flux® implant in deep sclerectomy.
In a retrospective analysis 17 patients were identified who underwent combined phacoemulsification-deep sclerectomy and implantation of SKGEL® in one eye and T-Flux® in the contralateral eye.
In eyes with SKGEL® the IOP decreased from 20.6+7.3 mm Hg to 14.8+5.3 mm Hg (-5.8 mm Hg or -28.1%), and in eyes with T-Flux® from 19.9+7.2 mm Hg to 14.7+3.3 mm Hg (-5.2 mm Hg or -26.1%, no statistically significant difference, p >0.05). Antiglaucoma medications with either implant decreased from initially 2.0+0.8 to 0.3+0.7. A qualified success was found in 17/17 eyes with T-Flux® and in 16/17 eyes with SKGEL®. Complete success was achieved in 14/17 eyes with T-Flux® and in 13/17 eyes with SKGEL®.
The IOP-lowering effect and safety of SKGEL® and T-Flux® seem to be comparable.